What Has Been the Growth Trajectory for the Gastroesophageal Reflux Disease Therapeutics Market in Recent Years?
The gastroesophageal reflux disease therapeutics market has seen considerable growth due to a variety of factors.
•The market size of therapeutics for gastroesophageal reflux disease has seen a consistent increase in recent years. It is predicted to expand from a value of $5.93 billion in 2024 to $6.14 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.6%.
The historic growth pattern can be associated with factors like lifestyle changes and dietary shifts, aging demographic, rise in awareness and diagnosis rates, prevalent stress-driven lifestyles, and increasing obesity levels.
How Does the Forecast Look for the Gastroesophageal Reflux Disease Therapeutics Market?
The gastroesophageal reflux disease therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• There is a projection for a significant rise in the size of the gastroesophageal reflux disease therapeutics market in the coming years. The expected growth rate is 6.5% compounded annually, reaching an estimated $7.89 billion by 2029.
Several factors are attributing to this expected growth during the forecast period, such as increased demand for fresh therapies, a rise in the ageing population, personalized therapeutic strategies, emphasis on non-drug interventions, and the emergence of biologic and cutting-edge therapies. The upcoming trends within this forecast period include a shift towards alternative therapies, focused research on gut health, new patient-centered care models, targeted approaches to raise gerd awareness, and the incorporation of digital health resources.
What Main Forces Are Fueling Expansion In The Gastroesophageal Reflux Disease Therapeutics Market?
The anticipated surge in gastroesophageal reflux disease is projected to fuel the expansion of the market for gastroesophageal reflux disease therapeutics. Gastroesophageal reflux disease is a long-term malady where stomach acid flows back into the esophagus, eliciting symptoms like heartburn and regurgitation, and possibly leading to complications. Therapeutics for this disease aim to lessen and manage acid reflux symptoms by neutralizing gut pH levels, reducing inflammation, and enhancing esophageal functionality. For example, according to an article by WebMed, a U.S.-based digital health news and information publisher, in September 2022, over 60 million American adults experience heartburn at least once a month and over 15 million endure daily heartburn. Additionally, the U.S. federal medical library, the National Library of Medicine, stated in July 2022 that GERD is one of the most frequently diagnosed digestive disorders in the U.S., with it occurring in 20% of the population and leading to substantial economic strain through direct and indirect costs, as well as adversely affecting quality of life. Consequently, the anticipated rise in gastroesophageal reflux disease is likely to bolster the gastroesophageal reflux disease therapeutics market.
What Are The Primary Segments In The Global Gastroesophageal Reflux Disease Therapeutics Market?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Super markets
4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
Pre-Book The Gastroesophageal Reflux Disease Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Gastroesophageal Reflux Disease Therapeutics Market?
Product innovation is a major trend in the therapeutics market for gastroesophageal reflux disease, as primary corporations in the market are concentrating on crafting unique medications to maintain their standing. For example, Phathom Pharmaceuticals, an American biopharmaceutical firm, launched a potassium-competitive acid blocker, VOQUEZNA (vonoprazan) in November 2023. This has been approved for treating all grades of erosive esophagitis, as well as for the relief of heartburn related to both erosive and non-erosive GERD. The clinical studies yielded impressive results, showing a 93% healing rate in patients who were treated with the 20 mg dosage, in contrast to the 85% rate for the standard proton pump inhibitor, lansoprazole.
Who Are the Key Players in the Gastroesophageal Reflux Disease Therapeutics Market?
Major companies operating in the gastroesophageal reflux disease therapeutics market include:
• Pfizer Inc.
• Johnson and Johnson
• Novartis AG
• Sanofi S.A.
• AstraZeneca plc
• Medtronic PLC
• GlaxoSmithKline plc
• Eisai Co. Ltd.
• Takeda Pharmaceutical Company Limited
• bioMerieux SA
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• CHEPLAPHARM Arzneimittel GmbH
• Daewoong Pharmaceutical Co. Ltd
• Ironwood Pharmaceuticals Inc.
• Sebela Pharmaceuticals Inc.
• Camber Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• EndoGastric Solutions
• RaQualia Pharma Inc
• TWi Pharmaceuticals Inc.
• Astellas Pharma Inc.
• SFJ Pharmaceuticals Group
• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Limited
What Is The Most Dominant Region In The Gastroesophageal Reflux Disease Therapeutics Market?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
